Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. - Wikidata - wikimedia - TriplyDB

Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.

Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.

http://www.wikidata.org/entity/Q39293482

about

Recent advances in understanding and managing cholestasis Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis Primary biliary cirrhosis: From bench to bedside Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy Nuclear Receptors as Therapeutic Targets in Liver Disease: Are We There Yet?Clinical application of transcriptional activators of bile salt transporters.Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial.Liver alkaline phosphatase: a missing link between choleresis and biliary inflammation.PPARα: A Master Regulator of Bilirubin Homeostasis Fibrates and cholestasis The Cholangiopathies.Advances in pharmacotherapy for primary biliary cirrhosis.Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis Nuclear receptors as drug targets in cholestatic liver diseases.Proposed therapies in primary biliary cholangitis.Upregulation of PDZK1 by Calculus Bovis Sativus May Play an Important Role in Restoring Biliary Transport Function in Intrahepatic Cholestasis.Nuclear-receptor-mediated regulation of drug- and bile-acid-transporter proteins in gut and liver.Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis.New therapies for primary biliary cirrhosis.New insights in the biology of ABC transporters ABCC2 and ABCC3: impact on drug disposition.It is time to change primary biliary cirrhosis (PBC): New nomenclature from "cirrhosis" to "cholangitis", and upcoming treatment based on unveiling pathology.Inhibition of JNK signalling mediates PPARα-dependent protection against intrahepatic cholestasis by fenofibrate.Emerging drugs for the treatment of Primary Biliary Cholangitis.Management of cholestatic disease in 2017.Treatment of primary biliary cholangitis ursodeoxycholic acid non-responders: A systematic review.Fibrates as adjuvant therapy for chronic cholestatic liver disease: its time has come.Primary biliary cholangitis: a comprehensive overview.From pathogenesis to novel therapies in the treatment of primary biliary cholangitis.New therapeutics in primary biliary cirrhosis: will there ever be light?Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.Tissue distribution and ontogeny of multidrug resistance protein 2, a phosphatidylcholine translocator, in rats.Differences in the Serum 4β-hydroxycholesterol Levels of Patients with Chronic HCV Infection: A Possible Impact on the Efficacy and Safety of IFN-free Treatment.Editor's Highlight: Clofibrate Decreases Bile Acids in Livers of Male Mice by Increasing Biliary Bile Acid Excretion in a PPARα-Dependent Manner.In vitro cytogenetic toxicity of bezafibrate in human peripheral blood lymphocytes.Investigational drugs in phase II clinical trials for primary biliary cholangitis.A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia.A functional classification of ABCB4 variations causing progressive familial intrahepatic cholestasis type 3.Primary biliary cholangitis: new treatments for an old disease.Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis.Guidelines for the management of primary biliary cirrhosis

P2860

Q26748537-F0944974-9C74-4DCE-A870-254795B557DA Q26778511-18A65985-147D-45AC-9E63-E102F8F215D0 Q26799419-FD2823F8-E2A8-4E37-82B6-5B4633CFCB21 Q26853649-F8FCED90-B2BC-4440-BFF5-7FB269985F44 Q28066233-29E40B5A-B604-455E-A2DF-CD0AD18A6604 Q33709930-B3B955C8-C6E7-4C02-8F99-7B5A7C6D2A04 Q33721771-B324B019-406C-4E3B-BF2C-6E5DB08861F6 Q34043010-30E63A55-E466-4F35-AD81-763A133713EE Q34053116-22BFA4AF-B46A-4CAA-A540-419BED8D0470 Q35889448-31FA09EE-1B07-4226-A4F4-F20D3B829E3D Q35942610-9FF559FE-0D12-4816-BD19-90D3B7948142 Q36116022-F82BF278-1D3F-42DE-86B7-58648FF07065 Q36752084-E39C1183-7B59-4A9A-BEF7-41ED55A62ED4 Q36786270-DCD5BB3E-47B5-4BA1-AF4A-F31BECA8DB77 Q37072380-5FA1336C-AB56-412C-AB38-4F6951E744FA Q37590885-82DFDDA0-22B5-473A-99E6-3CF50696BB18 Q38074991-7E568BF0-7760-48B5-903D-1914CDC0FD0A Q38174167-AC0BB2A7-0835-460E-B5C1-BEA5141ABFAE Q38261577-FDC9770A-9C22-434D-AB36-78CA3AB300BC Q38266172-D6452584-B295-4B4D-B81C-4D90532E2D3B Q38620686-E4015B85-CD26-4D0C-B302-6D3F92928E2C Q38711012-5038312E-07DC-4EE7-8DC7-1994165853D3 Q38744215-F93FCDA9-7A9F-4EA6-A1CE-9CE71FC3E09F Q38774857-DB341FF2-4DC3-43A2-A8FC-D81C8AD3452C Q39314534-B04C63FA-E700-48C1-87E3-91379EC1D959 Q42649890-365C99ED-0843-42C9-A32D-76752B0AB6F4 Q46078221-F5437776-51FC-447F-B502-74F717C1ECFE Q46135644-5C6725D6-5381-4593-BE9F-838D6401F739 Q46182874-428F932D-FBBB-4FF0-9400-CFDFC0D53AB7 Q47615113-B2F544EE-608C-4CC9-AD0A-ED07F6EF7828 Q48496557-4B432A6D-FFCB-4DCE-9999-0AB909254D95 Q49567497-3FFF484B-D918-495B-9210-3DAF3D5668B2 Q49650135-C0D523DD-B219-44F8-8775-989977A56C64 Q52801689-A855CAB6-4884-4BAF-8815-E48E0D9E3988 Q53098304-2FECEE6F-ACDA-4C3C-A138-20FCE98B6C68 Q53591523-29432139-BFD5-457D-85E4-19AA2BBB1982 Q53813239-82720129-4003-44A1-883A-B461CC6D4594 Q54390436-B4FD2C67-33DE-4918-9270-C8E357527971 Q55190939-88124F0A-1847-4247-A2A7-3B4948CC1E3C Q56429943-4EA677B6-D21C-4DAF-9FA8-8F7E086DCD72

P2860

Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.

http://www.wikidata.org/entity/Q39293482

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Anticholestatic effects of bez ...... ted with ursodeoxycholic acid.

@en

Anticholestatic effects of bez ...... ted with ursodeoxycholic acid.

@nl

type

label

Anticholestatic effects of bez ...... ted with ursodeoxycholic acid.

@en

Anticholestatic effects of bez ...... ted with ursodeoxycholic acid.

@nl

prefLabel

Anticholestatic effects of bez ...... ted with ursodeoxycholic acid.

@en

Anticholestatic effects of bez ...... ted with ursodeoxycholic acid.

@nl

P1433

Q39293482-66E6E325-5C45-4544-96F9-9E360307F743

P1476

Q39293482-90FC45FC-31FF-44D9-A405-04B4030D2F69

P2093

Q39293482-06C07950-85B4-4763-AD9E-A39822D07A34

Q39293482-1EBA7ACC-E507-464E-ADFC-3B8D8E886A6C

Q39293482-496B5E64-C5AE-450F-87D0-1D4E67849938

Q39293482-49C50B1A-B0D4-4EE1-B120-50F18E746A36

Q39293482-6659A916-7973-4C0F-BE02-3EE72AD9A697

Q39293482-6D6CE2C9-D196-47D9-A8CA-193DE310D363

Q39293482-7E7E1E6A-C68C-4A2F-9142-E9A5C79035E4

Q39293482-92D3A8E5-64A7-4766-B4A6-90AB68CFB2B3

Q39293482-CB306F12-57B9-4476-B8DD-92D61AA57D00

Q39293482-D998315C-D9F7-4BFA-8D79-0571813C7734

P2860

Q39293482-00834CAE-35FF-403B-B5F0-DD289FD436EB

Q39293482-053FC019-64BC-4814-A684-55B0453D499B

Q39293482-06D7919B-95F7-4BAE-A232-34501B2B83E9

Q39293482-092EF249-AF37-4330-BFE2-E02D2F9D7441

Q39293482-0D3271B8-4D09-441A-B808-5D00262BC8BC

Q39293482-121FEAED-E108-4DE2-A097-4B9E719093F4

Q39293482-13FDFCE3-2EA3-4909-943A-5032BB62A982

Q39293482-24054895-DB39-40A3-92A2-55DB846D352F

Q39293482-25085CB1-4890-4980-80D6-39FB6B74CD3E

Q39293482-31CBFB4E-EEBD-4F96-91C3-783DEAD90A1A

P304

Q39293482-7AA1F3C5-EF13-44B5-B278-AACB3F92B2A1

P31

Q39293482-3D0A3937-987A-4BEF-B7ED-8DECFE7E0467

P356

Q39293482-2069A07C-1813-4F1F-890E-1CF4A7F10389

P407

Q39293482-25A9F3C2-5852-48C3-AA25-380109C30287

P433

Q39293482-B8859D95-E9DA-4BB9-961E-1827ED427F8E

P478

Q39293482-087BE4BB-CAE9-4F55-8836-329A99815E82

P577

Q39293482-36EEEAB3-22FF-46B3-87FD-21EB5D00F2D5

P698

Q39293482-326C88C7-542A-4E57-991B-FA0F312F7AF5

P356

P1433

P1476

Anticholestatic effects of bez ...... ted with ursodeoxycholic acid.

@en

P2093

Akira Honda

http://www.w3.org/2001/XMLSchema#string

Hajime Takikawa

http://www.w3.org/2001/XMLSchema#string

Junichi Iwamoto

http://www.w3.org/2001/XMLSchema#string

Makoto Nakamuta

http://www.w3.org/2001/XMLSchema#string

Michio Imawari

http://www.w3.org/2001/XMLSchema#string

Tadashi Ikegami

http://www.w3.org/2001/XMLSchema#string

Takeshi Hirayama

http://www.w3.org/2001/XMLSchema#string

Teruo Miyazaki

http://www.w3.org/2001/XMLSchema#string

Yasushi Matsuzaki

http://www.w3.org/2001/XMLSchema#string

Yoshifumi Saito

http://www.w3.org/2001/XMLSchema#string

P2860

The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity

The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux

A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group

Effects of long-term rifampicin administration in primary biliary cirrhosis

The PPARs: from orphan receptors to drug discovery

A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues.

The PXR is a drug target for chronic inflammatory liver disease.

Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA.

Chemical genomics: functional analysis of orphan nuclear receptors in the regulation of bile acid metabolism.

4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans.

P304

1931-1941

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.26018

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22911624

http://www.w3.org/2001/XMLSchema#string